Expression of p300 protects cardiac myocytes from apoptosis in vivo

T Kawamura, K Hasegawa, T Morimoto… - Biochemical and …, 2004 - Elsevier
T Kawamura, K Hasegawa, T Morimoto, E Iwai-Kanai, S Miyamoto, Y Kawase, K Ono
Biochemical and biophysical research communications, 2004Elsevier
Doxorubicin is an anti-tumor agent that represses cardiac-specific gene expression and
induces myocardial cell apoptosis. Doxorubicin depletes cardiac p300, a transcriptional
coactivator that is required for the maintenance of the differentiated phenotype of cardiac
myocytes. However, the role of p300 in protection against doxorubicin-induced apoptosis is
unknown. Transgenic mice overexpressing p300 in the heart and wild-type mice were
subjected to doxorubicin treatment. Compared with wild-type mice, transgenic mice …
Doxorubicin is an anti-tumor agent that represses cardiac-specific gene expression and induces myocardial cell apoptosis. Doxorubicin depletes cardiac p300, a transcriptional coactivator that is required for the maintenance of the differentiated phenotype of cardiac myocytes. However, the role of p300 in protection against doxorubicin-induced apoptosis is unknown. Transgenic mice overexpressing p300 in the heart and wild-type mice were subjected to doxorubicin treatment. Compared with wild-type mice, transgenic mice exhibited higher survival rate as well as more preserved left ventricular function and cardiac expression of α-sarcomeric actin. Doxorubicin induced myocardial cell apoptosis in wild-type mice but not in transgenic mice. Expression of p300 increased the cardiac level of bcl-2 and mdm-2, but not that of p53 or other members of the bcl-2 family. These findings demonstrate that overexpression of p300 protects cardiac myocytes from doxorubicin-induced apoptosis and reduces the extent of acute heart failure in adult mice in vivo.
Elsevier